Cellid IPO To Fund First-In-Class Cancer Immunotherapeutic Vaccines
Executive Summary
After using government financial support to fund its early-stage clinical trials, Korean bioventure Cellid aims to further progress its first-in-class, cell-based cancer immunotherapeutic vaccines through an initial public offering in February.